UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCSF Helen Diller Family Comprehensive Cancer Center


Dr. Chien on Treatment Duration in HER2+ Breast Cancer

October 04, 2018

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment duration in HER2-positive breast cancer.

Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCL

October 02, 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Dr. Atreya Discusses Maintenance Therapy for CRC

May 29, 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

Dr. Atreya on Questions Remaining With Tumor Sidedness in CRC

April 25, 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

Dr. Wolf on the Treatment of High-Risk Patients With Multiple Myeloma

April 20, 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.

Role of Immunotherapies Emerging in Gastric/GEJ Cancers

April 11, 2018

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

Dr. Gordan on Molecular Diagnostics in Biliary Tract Cancers

March 22, 2018

John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.

Dr. Van Loon on the PROSPECT Trial

March 21, 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

Dr. Kelley Discusses the Rising Incidence of HCC

March 20, 2018

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.

Dr. Tempero on Emerging Agents in Pancreatic Cancer

March 20, 2018

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.

x